Interactions between hyperthermia and cytotoxic drugs

Peritoneal Carcinomatosis: A Multidisciplinary Approach

Volumn , Issue , 2007, Pages 185-193

  Hildebrandt, Bert ^a   Wust, Peter ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ANIMAL; DRUG RESISTANCE; HEAT; HUMAN; HYPERTHERMIC THERAPY; METHODOLOGY; MULTIMODALITY CANCER THERAPY; NEOPLASM; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DRUG RESISTANCE, NEOPLASM; HEAT; HUMANS; HYPERTHERMIA, INDUCED; NEOPLASMS;

EID: 84892802172     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-48993-3_11     Document Type: Chapter

References (37)

1. Dewhirst MW, Vujaskovic Z, Jones E, Thrall D (2005) Re-setting the biologic rationale for thermal therapy. Int J Hyperthermia 21(8):779-790
2. Hildebrandt B, Wust P, Ahlers O, Dieing A, Sreenivasa G, Kerner T, et al (2002) The cellular and molecular basis of hyperthermia. Crit Rev Oncol Hematol 43(1):33-56
3. Lepock JR (2005) How do cells respond to their thermal environment? Int J Hyperthermia 21(8):681-687
4. Song CW, Park HJ, Lee CK, Griffin R (2005) Implications of increased tumor blood flow and oxygenation caused by mild temperature hyperthermia in tumor treatment. Int J Hyperthermia 21(8):761-767
5. Streffer C (1990) Biological basis of thermotherapy (with special reference to oncology). In: Gautherie M, editor. Biological basis of oncologic thermotherapy. Berlin, Heidelberg, New York: Springer; p1-72
6. Vanakoski J, Seppä lä T (1998) Heat exposure and drugs. Clin Pharmacokinet 34(4):311-322
7. Kampinga HH (2006) Cell biological effects of hyperthermia alone or combined with radiation or drugs: a short introduction to newcomers in the field. Int J Hyperthermia 22(3):191-196
8. Takemoto M, Kuroda M, Urano M, Nishimura Y, Kawasaki S, Kato H, et al (2003) The effect of various chemotherapeutic agents given with mild hyperthermia on different types of tumours. Int J Hyperthermia 19(2):193-203
9. Urano M, Kuroda M, Nishimura Y (1999) For the clinical application of thermochemotherapy given at mild temperatures. Int J Hyperthermia. 15(2):79-107
10. Katschinski DM, Jacobson EL, Wiedemann GJ, Robins HI (2001) Modulation of VP-16 cytotoxicity by carboplatin and 41.8 degrees C hyperthermia. J Cancer Res Clin Oncol 127(7):425-432
11. van Bree C, Beumer C, Rodermond HM, Haveman J, Bakker PJ (1999) Effectiveness of 2',2'difluorodeoxycytidine (Gemcitabine) combined with hyperthermia in rat R-1 rhabdomyosarcoma in vitro and in vivo. Int J Hyperthermia 15(6):549-556
12. Cividalli A, Cruciani G, Livdi E, Pasqualetti P, Tirindelli Danesi D (1999) Hyperthermia enhances the response of paclitaxel and radiation in a mouse adenocarcinoma. Int J Radiat Oncol Biol Phys 1;44(2):407-412
13. Beck WT, Dalton WS (1997) Mechanisms of drug resistance. In: DeVita VTj, Hellmann S, Rosenberg SA, editors. Cancer-Principles and practice of Oncology. Philadelphia, New York: Lippincott-Raven publishers, p498-512
14. Hettinga JV, Konings AW, Kampinga HH (1997) Reduction of cellular cisplatin resistance by hyperthermia-a review. Int J Hyperthermia 13(5):439-457
15. Souslova T, Averill-Bates DA (2004) Multidrug-resistant hela cells overexpressing MRP1 exhibit sensitivity to cell killing by hyperthermia: interactions with etoposide. Int J Radiat Oncol Biol Phys 1;60(5):1538-1551
16. Stein U, Rau B, Wust P, Walther W, Schlag PM (1999) Hyperthermia for treatment of rectal cancer: evaluation for induction of multidrug resistance gene (mdr1) expression. Int J Cancer 80(1):5-12
17. Stein U, Jurchott K, Schlafke M, Hohenberger P (2002) Expression of multidrug resistance genes MVP, MDR1, and MRP1 determined sequentially before, during, and after hyperthermic isolated limb perfusion of soft tissue sarcoma and melanoma patients. J Clin Oncol 1;20(15):3282-3292
18. Kregel KC (2002) Heat Shock proteins: modifying factors in physiological stress response and aquired thermotolerance. J Appl Physiol 92:2177-2186
19. Li GC, Mivechi NF, Weitzel G (1995) Heat shock proteins, thermotolerance, and their relevance for clinical hyperthermia. Int J Hyperthermia 11(4):459-488
20. Hildebrandt B, Hegewisch-Becker S, Kerner T, Nierhaus A, Bakhshandeh-Bath A, Janni W, et al (2005) Current status of radiant whole-body hyperthermia at temperatures > 41.5°C and practical guidelines for the treatment of adults. The German "Interdisciplinary Working Group on Hyperthermia". Int J Hyperthermia 21(2):169-183
21. Wust P, Hildebrandt B, Sreenivasa G, Rau B, Gellermann J, Riess H, et al (2002) Hyperthermia in combined treatment of cancer. Lancet Oncol 3(8):487-497
22. Yonemura Y, de Aretxabala X, Fujimura T, Fushida S, Katayama K, Bandou E, et al (2001) Intraoperative chemohyperthermic peritoneal perfusion as an adjuvant to gastric cancer: final results of a randomised controlled study. Hepatogastroenterology 48(42):1776-1782
23. Robins Hl, Cohen JD, Schmitt CL, Tutsch KD, Feierabend C, Arzoomanian RZ, et al (1993) Phase I Clinical Trial of Carboplatin and 41.8°C Whole-Body Hyperthermia in Cancer Patients. J Clin Oncol 9:1787-1794
24. Wiedemann G, d'Oleire F, Knop E, Eleftheriadis S, Bucsky P, Feddersen S, et al (1994) Ifosfamide and Carboplatin combined with 41.8 °C whole-body hyperthermia in patients with refractory sarcoma and malignant teratoma. Cancer Res 54:5346-5350
25. Formenti SC, Shrivastava PN, Sazozink M, et al (1996) Abdominopelvic hyperthermia and intraperitoneal carboplatin in epithelial ovarian cancer: feasibility, tolerance, and pharmacology. Int J Radiat Oncol Biol Phys 35(5):993-1001
26. Jones E, Alvarez Secord A, Prosnitz LR, Samulski TV, Oleson JR, Berchuck A, et al (2006) Intra-peritoneal cisplatin and whole abdomen hyperthermia for relapsed ovarian carcinoma. Int J Hyperthermia 22(2):161-172
27. Hauck ML, Zalutsky MR (2005) Enhanced tumour uptake of radiolabelled antibodies by hyperthermia: Part I: Timing of injection relative to hyperthermia. Int J Hyperthermia 21(1):1-11
28. Hauck ML, Zalutsky MR (2005) Enhanced tumour uptake of radiolabelled antibodies by hyperthermia. Part II: Application of the thermal equivalency equation. Int J Hyperthermia 21(1):13-27
29. Kinuya S, Yokoyama K, Hiramatsu T, Konishi S, Watanabe N, Shukei N, et al (2000) Optimal timing of hyperthermia in combined radioimmunotherapy. Cancer Biother Radiopharm 15(4):373-379
30. Kinuya S, Yokoyama K, Michigishi T, Tonami N. Optimization of radio-immunotherapy interactions with hyperthermia. Int J Hyperthermia. 2004 Mar;20(2):190-200
31. Brade AM, Ngo D, Szmitko P, Li PX, Liu FF, Klamut HJ (2000) Heatdirected gene targeting of adenoviral vectors to tumor cells. Cancer Gene Ther 7(12):1566-1574
32. Huang Q, Hu JK, Lohr F, Zhang L, Braun R, Lanzen J, et al (2000) Heat-induced gene expression as a novel targeted cancer gene therapy strategy. Cancer Res 1;60(13):3435-3439
33. Lee YJ, Lee H, Borrelli MJ (2002) Gene transfer into human prostate adenocarcinoma cells with an adenoviral vector: Hyperthermia enhances a double suicide gene expression, cytotoxicity and radiotoxicity. Cancer Gene Ther 9(3):267-274
34. Kong G, Dewhirst MW (1999) Hyperthermia and liposomes. Int J Hyperthermia 15(5):345-370
35. Lindner LH, Eichhorn ME, Eibl H, Teichert N, Schmitt-Sody M, Issels RD, et al (2004) Novel temperature-sensitive liposomes with prolonged circulation time. Clin Cancer Res 15;10(6):2168-2178
36. Johannsen M, Thiesen B, Gneveckow U, Taymoorian K, Waldofner N, Scholz R, et al (2006) Thermotherapy using magnetic nanoparticles combined with external radiation in an orthotopic rat model of prostate cancer. Prostate 1;66(1):97-104
37. Moroz P, Jones SK, Gray BN (2002) Magnetically mediated hyperthermia: current status and future directions. Int J Hyperthermia. 18(4):267-284